NEW YORK (GenomeWeb News) – GE Healthcare said this week that Life Sciences CEO and President Peter Ehrenheim will retire this year and will be replaced by Kieran Murphy, who currently is head of Global Commercial Operations, Life Sciences.
Murphy will step into job in April, and after a period of transition, Ehrenheim will retire at the end of July. Ehrenheim was a mechanical engineer with Pharmacia, which was acquired by Amersham in 1997, which in turn was acquired by GE. Murphy was CEO of Whatman, which was acquired by GE Healthcare in 2008. He also has worked at Janssen Pharmaceutical, at Vericore, and at Novartis.
Cepheid said in a filing with the Securities and Exchange Commission that Mitchell Mroz plans to retire from his seat on the board of directors. Mroz will not stand for re-election to his Class III director position at the company's annual shareholder meeting in April, the company said.
NanoString has hired Chris Grimley to be VP of marketing and communications and Katherine Webster to be VP of worldwide sales. Grimley recently was senior director of Genomics Marketing at Agilent Technologies, and he spent 14 years working in various senior management positions at Applied Biosystems. Webster most recently was senior sales director at Qiagen, and before that she was a VP of sales for the 454 Sequencing Center at 454 Life Sciences.
Great Basin Corporation has hired Andrew Olson to be VP of sales, Sandra Nielson to be VP of marketing, and it has named Brian Hicke, Charles Owen, and Wesley Lindsey to posts on its R&D team. Olson recently held a similar title at Signature Genomics, and Nielson was a senior director of marketing for Pearson PLC's Data Solutions business unit. Hicke till take over the position of director of research; Owen will serve as director of engineering; and Lindsey will be director of product development.
Mitomics has named Luis Martin to be chief commercial officer, and it has appointed Stephen Galliker to serve on its board of directors. Martin has spent 20 years in senior management in the biotech sector, including serving as director at PREVENT, as managing director and founder of Lumar Management Consulting, and he worked in R&D at Arius Research and at Gensel Biotechnologies. Galliker currently serves on the board of directors at RXi Pharmaceuticals, and he formerly was CFO and executive VP of finance and administration at Dyax.
Sigma-Aldrich has named Frank Wicks to serve as president of research, replacing Dave Smoller, who will take over the CSO post. The company also has promoted Gerrit van den Dool to be VP and managing director for the US and Canada region business.
The aim of the reorganization is to enable the company to accelerate strategic initiatives in key areas and to emphasize the materials science market.
Wicks will be responsible for the firm's entire portfolio of research products, including its Research Essentials and Research Biotech business. Smoller will be charged with developing the company's global R&D strategy for all research initiatives, and with managing its IP portfolio and licensing activity. Van Den Dool formerly led North American sales and Global Accounts at the company.
Mark Lathrop has been hired to be scientific director of the McGill University and Genome Quebec Innovation Centre. Lathrop was co-founder and first scientific director of the Wellcome Trust Centre for Human Genetics, and in 1998 he helped found the National Genotyping Center in Paris.
Promoted? Changing jobs? GenomeWeb wants to know. E-mail [email protected] to appear in People In The News, a weekly roundup of industry comings and goings.